Education
About Us
Working with TipRanks
Follow Us
Takeda Pharmaceutical Co Ltd (JP:4502)
:4502
RESEARCH TOOLSreports
Total Valuation
Takeda Pharmaceutical Co has a market cap or net worth of $6.89T. The enterprise value is ¥10.60T.
Market Cap$6.89T
Enterprise Value¥10.60T
Share Statistics
Takeda Pharmaceutical Co has 1,590,961,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,590,961,700
Owned by Insiders―
Owned by Institutions<0.01%
Financial Efficiency
Takeda Pharmaceutical Co’s return on equity (ROE) is 0.02 and return on invested capital (ROIC) is 2.67%.
Return on Equity (ROE)0.02
Return on Assets (ROA)<0.01
Return on Invested Capital (ROIC)2.67%
Return on Capital Employed (ROCE)0.04
Revenue Per Employee92.97M
Profits Per Employee2.19M
Employee Count49,281
Asset Turnover0.32
Inventory Turnover1.83
Valuation Ratios
The current PE Ratio of Takeda Pharmaceutical Co is 64.56. Takeda Pharmaceutical Co’s PEG ratio is 0.55.
PE Ratio64.56
PS Ratio0.00
PB Ratio1.06
Price to Fair Value1.00
Price to FCF19.65
Price to Operating Cash Flow6.91
PEG Ratio0.55
Income Statement
In the last 12 months, Takeda Pharmaceutical Co had revenue of 4.58T and earned 107.93B in profits. Earnings per share was 68.36.
Revenue4.58T
Gross Profit2.36T
Operating Income523.11B
Pretax Income179.07B
Net Income107.93B
EBITDA1.15T
Earnings Per Share (EPS)68.36
Cash Flow
In the last 12 months, operating cash flow was 962.49B and capital expenditures -281.15B, giving a free cash flow of 701.06B billion.
Operating Cash Flow962.49B
Free Cash Flow701.06B
Free Cash Flow per Share440.65
Dividends & Yields
Takeda Pharmaceutical Co pays an annual dividend of ¥98, resulting in a dividend yield of 4.43%
Dividend Per Share¥98
Dividend Yield4.43%
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.52
52-Week Price Change9.18%
50-Day Moving Average4.24K
200-Day Moving Average4.16K
Relative Strength Index (RSI)59.61
Average Volume (3m)3.91M
Important Dates
Takeda Pharmaceutical Co upcoming earnings date is Jul 30, 2025, TBA Not Confirmed.
Last Earnings DateMay 8, 2025
Next Earnings DateJul 30, 2025
Ex-Dividend DateMar 28, 2025
Financial Position
Takeda Pharmaceutical Co as a current ratio of 1.01, with Debt / Equity ratio of 68.97%
Current Ratio1.01
Quick Ratio0.52
Debt to Market Cap0.65
Net Debt to EBITDA3.59
Interest Coverage Ratio2.49
Taxes
In the past 12 months, Takeda Pharmaceutical Co has paid 66.94B in taxes.
Income Tax66.94B
Effective Tax Rate0.37
Enterprise Valuation
Takeda Pharmaceutical Co EV to EBITDA ratio is 9.65, with an EV/FCF ratio of 14.57.
EV to Sales2.42
EV to EBITDA9.65
EV to Free Cash Flow14.57
EV to Operating Cash Flow11.53
Balance Sheet
Takeda Pharmaceutical Co has $385.11B in cash and marketable securities with ¥4.52T in debt, giving a net cash position of $4.13T billion.
Cash & Marketable Securities$385.11B
Total Debt¥4.52T
Net Cash$4.13T
Net Cash Per Share$2.60K
Tangible Book Value Per Share-$1.28K
Margins
Gross margin is 69.11%, with operating margin of 11.42%, and net profit margin of 2.36%.
Gross Margin69.11%
Operating Margin11.42%
Pretax Margin3.91%
Net Profit Margin2.36%
EBITDA Margin25.11%
EBIT Margin8.49%
Analyst Forecast
The average price target for Takeda Pharmaceutical Co is $5,038.65, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$5,038.65
Price Target Upside15.86% Upside
Analyst ConsensusModerate Buy
Analyst Count7
Revenue Growth Forecast7.45%
EPS Growth Forecast-25.77%